B,

Shin Lee1,2, Kei Fujita1,2, Tetsuji Morishita3,4

  • 1Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.

Cancers
|September 28, 2023
PubMed
概括

在一线化疗期间保持平均相对剂量强度 (ARDI) 对扩散大B细胞淋巴瘤患者至关重要. 循环4-6的ARDI下降显著恶化了整体存活率,突出了早期治疗强度.